Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd.

Published on Jun 1, 2018in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2018.36.15_SUPPL.E24206
Daisuke Okajima4
Estimated H-index: 4
(Daiichi Sankyo),
Satoru Yasuda3
Estimated H-index: 3
(Daiichi Sankyo)
+ 13 AuthorsToshinori Agatsuma12
Estimated H-index: 12
(Daiichi Sankyo)
e24206Background: DS-1062a is a trophoblast cell surface protein 2 (TROP2)-targeting antibody-drug conjugate (ADC) comprised of a humanized anti-TROP2 monoclonal antibody, enzymatically cleavable p...
📖 Papers frequently viewed together
15 Citations
4 Authors (Yoko Nagai, ..., Osamu Ando)
24 Citations
4 Citations
Cited By5
#1Yusuke Sayama (Tohoku University)H-Index: 7
#2Mika K. Kaneko (Tohoku University)H-Index: 30
Last. Yukinari Kato (Tohoku University)H-Index: 41
view all 7 authors...
Abstract TROP2 is a type I transmembrane glycoprotein originally identified in human trophoblast cells that is overexpressed in several types of cancer. To better understand the role of TROP2 in cancer, we herein aimed to develop a sensitive and specific anti-TROP2 monoclonal antibody (mAb) for use in flow cytometry, Western blot, and immunohistochemistry using a Cell-Based Immunization and Screening (CBIS) method. Two mice were immunized with N-terminal PA-tagged and C-terminal RAP/MAP-tagged T...
1 CitationsSource
Introduction: We describe a new, third-generation of antibody-drug conjugates (ADCs) having a high drug payload against topoisomerase I, important for DNA function, and targeting selective tumor antigens, predominantly TROP-2.Areas Covered: The historical development of ADCs is reviewed before presenting the current line of improved, third-generation ADCs targeting topoisomerase I, thus affecting DNA and causing double-stranded DNA breaks. Emphasis is given to explaining why sacituzumab goviteca...
15 CitationsSource
#2Ingrid SassoonH-Index: 2
Last. Marie-Priscille BrunH-Index: 2
view all 3 authors...
The targeted delivery of potent cytotoxic molecules into cancer cells is considered a promising anticancer strategy. The design of clinically effective antibody-drug conjugates (ADCs), in which biologically active drugs are coupled through chemical linkers to monoclonal antibodies, has presented challenges for pharmaceutical researchers. After 30 years of intensive research and development activities, only seven ADCs have been approved for clinical use; two have received fast-track designation a...
12 CitationsSource
ABSTRACTAntibody-drug conjugates (ADCs) that exploit the active metabolite SN-38, which is derived from the popular anticancer drug, irinotecan (a camptothecin that inhibits the nuclear topoisomera...
20 CitationsSource
#1Robert P. Lyon (Seattle Genetics)H-Index: 12
#1Robert Lyon (Protein Sciences)H-Index: 1
The antibody-drug conjugate (ADC) field has seen a remarkable expansion in the number of entrants in clinical studies. Many of these agents employ newer conjugation technologies that have been developed over the last decade that confer various attributes to the ADCs prepared with them, including stability, potency, and homogeneity. In many cases, these new ADCs appear demonstrably superior to earlier technologies in preclinical models of activity and toxicology, but the degree to which these imp...
25 CitationsSource